2-(对甲苯磺酰)乙酰胺 | 52345-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(对甲苯磺酰)乙酰胺
• 英文名称: p-tolylsulphonylacetamide
• 英文别名: 2-tosylacetamide；p-Toluolsulfonylacetamid；(toluene-4-sulfonyl)-acetic acid amide；(Toluol-4-sulfonyl)-essigsaeure-amid；C-p-Tolylsulfon-acetamid；2-[(4-methylphenyl)sulfonyl]acetamide；p-Tolylsulfon-essigsaeure-amid；2-(para-tolylsulfonyl)-acetamide；Acetamide, 2-[(4-methylphenyl)sulfonyl]-；2-(4-methylphenyl)sulfonylacetamide
• CAS: 52345-47-8
• 化学式: C₉H₁₁NO₃S
• mdl: MFCD00025523
• 分子量: 213.257
• InChiKey: ACGVKXZPAUDGMM-UHFFFAOYSA-N

物化性质

• 熔点：
  167 °C
• 密度：
  1.3185 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090
• 安全说明：
  S24/25

SDS

Name:	2-(P-Toluenesulfonyl)Acetamide Material Safety Data Sheet
Synonym:
CAS:	52345-47-8

Section 1 - Chemical Product MSDS Name:2-(P-Toluenesulfonyl)Acetamide Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
52345-47-8	2-(P-Toluenesulfonyl)Acetamide		257-864-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 52345-47-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 167 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H11NO3S
Molecular Weight: 213.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 52345-47-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(P-Toluenesulfonyl)Acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 52345-47-8: No information available.
Canada
CAS# 52345-47-8 is listed on Canada's NDSL List.
CAS# 52345-47-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 52345-47-8 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(对甲苯磺酰)乙酰胺 在 sodium hydroxide 、 溴 作用下， 生成 methyl-4-dibromomethanesulfonylbenzene
  参考文献：
  名称：

  Ziegler; Connor, Journal of the American Chemical Society, 1940, vol. 62, p. 1051

  摘要：

  DOI：
• 作为产物：
  描述：

  对甲苯磺酰乙酸 在 草酰氯 、 氨 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.0h， 生成 2-(对甲苯磺酰)乙酰胺
  参考文献：
  名称：

  Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

  摘要：

  DOI：

  10.1016/j.bmcl.2021.127846

文献信息

• A Concise Route to 2‐Sulfonylacetonitriles from Sodium Metabisulfite
  作者：Yanfang Yao、Ziqing Yin、Weiyun Chen、Wenlin Xie、Fu‐Sheng He、Jie Wu

  DOI：10.1002/adsc.202001243

  日期：2021.1.19

  A three‐component reaction of aryldiazonium tetrafluoroborates, sodium metabisulfite, and 3‐azido‐2‐methylbut‐3‐en‐2‐ol under mild conditions is described. By using abundant and cheap sodium metabisulfite as the sulfur dioxide surrogate, this protocol features good functional group compatibility, affording 2‐arylsulfonylacetonitriles in moderate to good yields. The reaction proceeds smoothly at room

  描述了在温和条件下四氟硼酸芳基重氮，偏亚硫酸氢钠和3-叠氮基-2-甲基丁-3-烯-2-醇的三组分反应。通过使用大量廉价的焦亚硫酸钠作为二氧化硫替代品，该方案具有良好的官能团相容性，可提供中等至良好收率的2-芳基磺酰基乙腈。反应在室温下平稳进行，不需要任何催化剂或添加剂。此外，该方法的合成效用通过将2-芳基磺酰基乙腈转化为2-芳基磺酰基乙酰胺和2-芳基磺酰基乙胺得到了证明。
• Proteasome inhibitors and methods of using the same
  申请人：Bernadini Raffaella

  公开号：US20050107307A1

  公开（公告）日：2005-05-19

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以通过抑制蛋白酶体活性等方式调节细胞凋亡。这些化合物和组合物可以用于诱导细胞凋亡并治疗癌症等疾病，以及与蛋白酶体活性直接或间接相关的其他疾病。
• PROTEASOME INHIBITORS AND METHODS OF USING THE SAME
  申请人：Bernardini Raffaella

  公开号：US20090291918A1

  公开（公告）日：2009-11-26

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节细胞凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导细胞凋亡和治疗癌症及其他与蛋白酶体活性直接或间接相关的疾病。
• Proteasome Inhibitors and Methods of Using the Same
  申请人：Bernardini Raffaella

  公开号：US20120041196A1

  公开（公告）日：2012-02-16

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导凋亡和治疗癌症以及其他与蛋白酶体活性直接或间接相关的疾病的方法。
• Proteasome Inhibitors And Methods Of Using The Same
  申请人：Cephalon, Inc.

  公开号：US20140088042A1

  公开（公告）日：2014-03-27

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导凋亡和治疗癌症和其他与蛋白酶体活性直接或间接相关的疾病的方法。